On October 6, 2020 Nanotein Technologies, Inc., an innovative startup biotechnology company in the San Francisco Bay Area, and Polaris Group, a developer of novel treatments for cancer, reported they have entered into a strategic partnership to advance Nanotein’s protein-based solutions for superior cellular therapy manufacturing (Press release, Polaris Pharmaceuticals, OCT 6, 2020, View Source [SID1234568215]). As part of the agreement, Polaris will manufacture research use only and GMP grade material for Nanotein. Polaris will receive equity and royalties for their manufacturing services.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!